DE2211299C3 - Verfahren zur Isolierung eines neuen Antibiotikums mit antiprotozoaler und kanzerostatischer Wirksamkeit - Google Patents
Verfahren zur Isolierung eines neuen Antibiotikums mit antiprotozoaler und kanzerostatischer WirksamkeitInfo
- Publication number
- DE2211299C3 DE2211299C3 DE19722211299 DE2211299A DE2211299C3 DE 2211299 C3 DE2211299 C3 DE 2211299C3 DE 19722211299 DE19722211299 DE 19722211299 DE 2211299 A DE2211299 A DE 2211299A DE 2211299 C3 DE2211299 C3 DE 2211299C3
- Authority
- DE
- Germany
- Prior art keywords
- ethyl acetate
- antibiotic
- antiprotozoal
- isolation
- extracted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000003115 biocidal effect Effects 0.000 title claims description 11
- 238000000034 method Methods 0.000 title claims description 6
- 230000000842 anti-protozoal effect Effects 0.000 title description 4
- 230000003327 cancerostatic effect Effects 0.000 title description 4
- 239000003904 antiprotozoal agent Substances 0.000 title description 3
- 238000002955 isolation Methods 0.000 title description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 239000003242 anti bacterial agent Substances 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 6
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002906 microbiologic effect Effects 0.000 claims description 2
- 241000215396 Dactylaria Species 0.000 claims 2
- 239000013543 active substance Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 5
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002024 ethyl acetate extract Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241000195622 Astasia Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222173 Candida parapsilosis Species 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241001149669 Hanseniaspora Species 0.000 description 1
- 244000286779 Hansenula anomala Species 0.000 description 1
- 235000014683 Hansenula anomala Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 244000285963 Kluyveromyces fragilis Species 0.000 description 1
- 235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
- 206010057168 Leishmania infections Diseases 0.000 description 1
- 208000004554 Leishmaniasis Diseases 0.000 description 1
- 241000228150 Penicillium chrysogenum Species 0.000 description 1
- 241000521553 Pichia fermentans Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- YBZRLMLGUBIIDN-UHFFFAOYSA-N Spicamycin Chemical compound O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000248418 Tetrahymena pyriformis Species 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 229940055022 candida parapsilosis Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS193571A CS154404B1 (ref) | 1971-03-17 | 1971-03-17 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE2211299A1 DE2211299A1 (de) | 1972-09-28 |
| DE2211299B2 DE2211299B2 (de) | 1975-05-07 |
| DE2211299C3 true DE2211299C3 (de) | 1975-12-18 |
Family
ID=5354975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19722211299 Expired DE2211299C3 (de) | 1971-03-17 | 1972-03-09 | Verfahren zur Isolierung eines neuen Antibiotikums mit antiprotozoaler und kanzerostatischer Wirksamkeit |
Country Status (4)
| Country | Link |
|---|---|
| CH (1) | CH572521A5 (ref) |
| CS (1) | CS154404B1 (ref) |
| DE (1) | DE2211299C3 (ref) |
| GB (1) | GB1389065A (ref) |
-
1971
- 1971-03-17 CS CS193571A patent/CS154404B1/cs unknown
-
1972
- 1972-03-09 DE DE19722211299 patent/DE2211299C3/de not_active Expired
- 1972-03-10 CH CH358772A patent/CH572521A5/xx not_active IP Right Cessation
- 1972-03-13 GB GB1169472A patent/GB1389065A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CH572521A5 (ref) | 1976-02-13 |
| DE2211299A1 (de) | 1972-09-28 |
| GB1389065A (en) | 1975-04-03 |
| CS154404B1 (ref) | 1974-04-30 |
| DE2211299B2 (de) | 1975-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2347682C2 (de) | Rapamycin, Verfahren zu seiner Herstellung und pharmazeutisches Mittel | |
| DE3006216C2 (de) | Monacolin K, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel | |
| DE2329486A1 (de) | Neue antibiotika und verfahren zu ihrer herstellung | |
| DE3028284A1 (de) | Monacolin k-derivate, verfahren zu ihrer herstellung und diese derivate enthaltende arzneimittel | |
| DE2167325C2 (de) | Antibiotikum A-201B und Verfahren zu seiner Herstellung | |
| DE2211299C3 (de) | Verfahren zur Isolierung eines neuen Antibiotikums mit antiprotozoaler und kanzerostatischer Wirksamkeit | |
| DE3048421C2 (de) | Antibiotische Substanz, Verfahren zu deren Herstellung und antimykotisches Mittel, welches diese enthält | |
| CH371217A (de) | Verfahren zur Herstellung von Distamycin und Distacin | |
| AT245169B (de) | Verfahren zur Herstellung des neuen Antibiotikums WG 696 | |
| DE2331891A1 (de) | O-acyliertes octa-2,3-dien-5,7-diin1-ol | |
| DE2108739C2 (de) | Antibiotikumkomplex S-3466 und Verfahren zu seiner Herstellung | |
| DE934429C (de) | Verfahren zur Erzeugung und Gewinnung eines Antibiotikums | |
| AT269354B (de) | Verfahren zur Herstellung eines neuen Antibiotikums | |
| AT208999B (de) | Verfahren zur Herstellung von Pimaricin | |
| CH342697A (de) | Verfahren zur Herstellung von Verbindungen von Antibiotika | |
| DE1617899A1 (de) | Lydimycin und Verfahren zu seiner Gewinnung | |
| AT267748B (de) | Verfahren zur Herstellung eines neuen Antibioticums | |
| DE2123639A1 (de) | S-Nitro-S-methylcarbamoyloxychinolin und Verfahren zu dessen Herstellung | |
| DE2200377A1 (de) | Verfahren zur Herstellung eines neuen Antibioticums | |
| DE2236599B2 (de) | Fungizides Antibiotikum, sowie Herstellung und Verwendung desselben | |
| CH565862A5 (en) | Fungicide contg antibiotic No. 1308 - non-toxic to fish and mammals | |
| DE2012695A1 (de) | Verfahren zur Herstellung von antibiotisch aktiven Substanzen in Gärmaischen | |
| DE1021129B (de) | Verfahren zur Gewinnung von Ayfactin | |
| CH657375A5 (en) | Process for the preparation of anthracycline antibiotics with anticancer activity, and microorganism strain as means for the preparation | |
| CH359517A (de) | Verfahren zur Herstellung von Pimaricin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) | ||
| E77 | Valid patent as to the heymanns-index 1977 | ||
| 8339 | Ceased/non-payment of the annual fee |